150 related articles for article (PubMed ID: 24985574)
21. Conjunctival cytokine expression in symptomatic moderate dry eye subjects.
Narayanan S; Miller WL; McDermott AM
Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2445-50. PubMed ID: 16723455
[TBL] [Abstract][Full Text] [Related]
22. Antioxidant and inflammatory cytokine in tears of patients with dry eye syndrome treated with preservative-free versus preserved eye drops.
Jee D; Park SH; Kim MS; Kim EC
Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):5081-9. PubMed ID: 24994869
[TBL] [Abstract][Full Text] [Related]
23. Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease - a randomised comparative study.
Amrane M; Creuzot-Garcher C; Robert PY; Ismail D; Garrigue JS; Pisella PJ; Baudouin C
J Fr Ophtalmol; 2014 Oct; 37(8):589-98. PubMed ID: 25127703
[TBL] [Abstract][Full Text] [Related]
24. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
Kim EC; Choi JS; Joo CK
Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Cortisol Phosphate in Hyaluronic Acid Vehicle in the Treatment of Dry Eye in Sjogren Syndrome.
Rolando M; Vagge A
J Ocul Pharmacol Ther; 2017 Jun; 33(5):383-390. PubMed ID: 28375792
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
[TBL] [Abstract][Full Text] [Related]
27. Sodium hyaluronate eye drops in the treatment of dry eye disease: an open label, uncontrolled, multi-centre trial.
Cheema A; Aziz T; Mirza SA; Siddiqi A; Maheshwary N; Khan MA
J Ayub Med Coll Abbottabad; 2012; 24(3-4):14-6. PubMed ID: 24669598
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of NAAGA efficacy in dry eye syndrome].
Brignole-Baudouin F; Robert PY; Creuzot-Garcher C; Olmiere C; Delval L; Baudouin C
J Fr Ophtalmol; 2009 Nov; 32(9):613-20. PubMed ID: 19854539
[TBL] [Abstract][Full Text] [Related]
30. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
31. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Sodium Hyaluronate/chondroitin Sulfate Preservative-free Ophthalmic Solution in the Treatment of Dry Eye: A Clinical Trial.
Belalcázar-Rey S; Sánchez Huerta V; Ochoa-Tabares JC; Altamirano Vallejo S; Soto-Gómez A; Suárez-Velasco R; García-Félix F; Baiza-Durán L; Olvera-Montaño O; Muñoz-Villegas P
Curr Eye Res; 2021 Jul; 46(7):919-929. PubMed ID: 33289602
[No Abstract] [Full Text] [Related]
34. Protecting the ocular surface and improving the quality of life of dry eye patients: a study of the efficacy of an HP-guar containing ocular lubricant in a population of dry eye patients.
Rolando M; Autori S; Badino F; Barabino S
J Ocul Pharmacol Ther; 2009 Jun; 25(3):271-8. PubMed ID: 19366323
[TBL] [Abstract][Full Text] [Related]
35. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Sosne G; Dunn SP; Kim C
Cornea; 2015 May; 34(5):491-6. PubMed ID: 25826322
[TBL] [Abstract][Full Text] [Related]
36. Effect of hypotonic 0.18% sodium hyaluronate eyedrops on inflammation of the ocular surface in experimental dry eye.
Oh HJ; Li Z; Park SH; Yoon KC
J Ocul Pharmacol Ther; 2014 Sep; 30(7):533-42. PubMed ID: 24766323
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye.
Nichols JJ; Bickle KM; Zink RC; Schiewe MD; Haque RM; Nichols KK
Eye Contact Lens; 2012 Mar; 38(2):73-9. PubMed ID: 22157392
[TBL] [Abstract][Full Text] [Related]
38. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
39. The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment.
Jirsova K; Brejchova K; Krabcova I; Filipec M; Al Fakih A; Palos M; Vesela V
Curr Eye Res; 2014 Jan; 39(1):21-30. PubMed ID: 24074049
[TBL] [Abstract][Full Text] [Related]
40. Comparative analysis of carmellose 0.5% versus hyaluronate 0.15% in dry eye: a flow cytometric study.
Sanchez MA; Torralbo-Jimenez P; Giron N; de la Heras B; Herrero Vanrell R; Arriola-Villalobos P; Diaz-Valle D; Alvarez-Barrientos A; Benitez-Del-Castillo JM
Cornea; 2010 Feb; 29(2):167-71. PubMed ID: 20023577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
